Prostate Cancer - Results from #1740

VALIDATION OF METASTASIS-FREE SURVIVAL AS A SURROGATE ENDPOINT FOR OVERALL SURVIVAL IN LOCALIZED PROSTATE CANCER IN THE ERA OF DOCETAXEL FOR CASTRATION RESISTANT PROSTATE CANCER. December 11, 2023

Co-occurring BRCA2/SPOP Mutations Predict Exceptional Poly (ADP-ribose) Polymerase Inhibitor Sensitivity in Metastatic Castration-Resistant Prostate Cancer. December 11, 2023

Dosimetric predictors for genitourinary toxicity in MR-guided stereotactic body radiation therapy (SBRT): Substructure with fraction-wise analysis. December 8, 2023

The Impact of Delayed Radical Prostatectomy on Recurrence Outcomes After Initial Active Surveillance: Results from a Large Institutional Cohort. December 8, 2023

Illustration of association between change in prostate-specific antigen (PSA) values and time to tumor status after treatment for prostate cancer patients: a joint modelling approach. December 8, 2023

Cost Effectiveness of Systemic Treatment Intensification for Metastatic Hormone-sensitive Prostate Cancer: Is Triplet Therapy Cost Effective? December 8, 2023

Prostate volume variation during 1.5T MR-guided adaptive stereotactic body radiotherapy (SBRT) and correlation with treatment toxicity. December 8, 2023

Reproducibility and Accuracy of the PRIMARY Score on PSMA PET and of PI-RADS on Multiparametric MRI for Prostate Cancer Diagnosis Within a Real-World Database. December 7, 2023

Renal and Multiorgan Safety of 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer in the VISION Dosimetry Substudy. December 7, 2023

Comparison of Multiple Segmentation Methods for Volumetric Delineation of Primary Prostate Cancer with Prostate-Specific Membrane Antigen-Targeted 18F-DCFPyL PET/CT. December 7, 2023

Association of PSMA PET-derived Parameters and Outcomes of Patients Treated for Oligorecurrent Prostate Cancer. December 7, 2023

Patient and physician perspectives on treatments for low-risk prostate cancer: a qualitative study. December 7, 2023

Activation of Dendritic Cells Isolated from the Blood of Patients with Prostate Cancer by Ex Vivo Fluid Shear Stress Stimulation. December 6, 2023

Long-Term Impact of Medicaid Expansion on Prostate Cancer Screening. December 6, 2023

Major adverse cardiovascular events of enzalutamide versus abiraterone in prostate cancer: a retrospective cohort study. December 6, 2023

First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial. December 6, 2023

Positive Surgical Margins After Anterior Robot-assisted Radical Prostatectomy: Assessing the Learning Curve in a Multi-institutional Collaboration. December 6, 2023

Adipose triglyceride lipase is a therapeutic target in advanced prostate cancer that promotes metabolic plasticity. December 5, 2023

Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial. December 5, 2023

Recurrent prostate cancer: combined role for MRI and PSMA-PET in 68Ga-PSMA-11 PET/MRI. December 5, 2023

Page 88 of 1438